- Home
- NREF vs MRSN Comparison
NREF vs MRSN Comparison
Compare NREF & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NREF
- MRSN
- Stock Information
- Founded
- NREF 2019
- MRSN 2001
- Country
- NREF United States
- MRSN United States
- Employees
- NREF N/A
- MRSN N/A
- Industry
- NREF Real Estate Investment Trusts
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- NREF Real Estate
- MRSN Health Care
- Exchange
- NREF Nasdaq
- MRSN Nasdaq
- Market Cap
- NREF 310.3M
- MRSN 252.0M
- IPO Year
- NREF 2020
- MRSN 2017
- Fundamental
- Price
- NREF $15.67
- MRSN $0.62
- Analyst Decision
- NREF Hold
- MRSN Buy
- Analyst Count
- NREF 4
- MRSN 6
- Target Price
- NREF $14.75
- MRSN $6.00
- AVG Volume (30 Days)
- NREF 43.6K
- MRSN 7.3M
- Earning Date
- NREF 02-27-2025
- MRSN 02-26-2025
- Dividend Yield
- NREF 12.76%
- MRSN N/A
- EPS Growth
- NREF N/A
- MRSN N/A
- EPS
- NREF 1.32
- MRSN N/A
- Revenue
- NREF $73,164,000.00
- MRSN $34,837,000.00
- Revenue This Year
- NREF N/A
- MRSN N/A
- Revenue Next Year
- NREF $34.61
- MRSN N/A
- P/E Ratio
- NREF $11.84
- MRSN N/A
- Revenue Growth
- NREF 224.04
- MRSN N/A
- 52 Week Low
- NREF $12.63
- MRSN $0.56
- 52 Week High
- NREF $18.09
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- NREF 47.65
- MRSN 20.37
- Support Level
- NREF $14.50
- MRSN $0.56
- Resistance Level
- NREF $15.75
- MRSN $1.45
- Average True Range (ATR)
- NREF 0.46
- MRSN 0.14
- MACD
- NREF 0.03
- MRSN -0.06
- Stochastic Oscillator
- NREF 78.13
- MRSN 6.49
About NREF NexPoint Real Estate Finance Inc.
NexPoint Real Estate Finance Inc is a real estate investment trust. It provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.